Navigation Links
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Date:7/16/2008

merger of Encode Pharmaceuticals. In March 2008, Raptor acquired an exclusive, worldwide license to the intellectual property and development rights for use of Cysteamine and DR Cysteamine for the treatment of NASH. The Company plans to initiate a Phase 2a clinical trial in collaboration with the University of California, San Diego ("UCSD") to evaluate Cysteamine in patients with NASH. In May 2008, Raptor received orphan drug designation from the FDA for DR Cysteamine for the treatment of Huntington's Disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTide(TM), WntTide(TM) and NeuroTrans(TM).

For additional information, please visit http://www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limit
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Raptor Pharmaceuticals Provides Update of Product Programs
3. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
7. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
10. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... July 30, 2015  Today we bring you a special edition of #MedicareMonday on ... you about some of our Medicare resources and continue highlighting the success of the ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... , WASHINGTON, Dec. 17 ... is adding new meaning to the word "relief" this Christmas ... American Development Foundation,s (PADF) request for cash assistance that allows ... that are still recovering from hurricanes and to the country,s ...
... A 58-year-old man who lives in Corona, Queens came to the emergency ... in his left arm. Although he did not realize it at ... as the first patient in the United States to be treated for ... tumor, and today his recovery is going well. Known as brachytherapy, ...
Cached Medicine Technology:Pitcher Joaquin Benoit, PADF Team Up to Send a Much-Needed Christmas Present to Haiti's Hospitals 2Novel Radiation Therapy to Treat Lung Cancer Used for the First Time in United States, at New York Hospital Queens 2Novel Radiation Therapy to Treat Lung Cancer Used for the First Time in United States, at New York Hospital Queens 3
(Date:8/1/2015)... Winamac, In (PRWEB) , ... August 02, 2015 , ... ... this month which will help the continuity of care for patients at this natural ... afraid of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to ...
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... The ... concern among both men and women often causing pain and discomfort. Those who spend ... this circulatory problem, and Northeast Houston Vein Center is doing what it can to ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with ... of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... increase in the incidence of malignant tumors, lymphomas ... of aspartame appears // to link the artificial ... a study accepted for publication today by the ... of the study, the first to demonstrate multipotential ...
... slowing the progression of Alzheimer’s’ disease. The study was ... // . ,The research team assessed the degree ... 342 patients attending a memory clinic. They then monitored ... The average age of the patients was 73. Most ...
... cases in China and Indonesia, the World Health Organization (WHO) ... with the H5N1 // avian influenza virus that has resulted ... birds. ,More than half the people infected – ... the announcement from Beijing officials November 16 that its Centre ...
... destination was the highlight of presentations made at the ... for Tourism Renuka Chowdhury, who // inaugurated the India ... only is India known for its hospitality, but also ... know how to do the best"., ,Chowdhury released ...
... used in a leading private hospital in New Delhi. ... technology. This will pave way for further 'bloodless' surgeries. ... its new KTP laser, surgery would become a bloodless ... Earlier, patients had to stay at least five days ...
... the use of Actemra in the treatment of rheumatoid ... treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs ... found to provide symptomatic relief and improve sensation of ... disease in which the lining of the joints becomes ...
Cached Medicine News:Health News:Artificial Sweetners Not Really Safe?, 2Health News:Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis 2
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Convenient: accommodates stomas up to 102 mm; wide bottom opening permits hand access; attached pouch closure....
FlexWear is a cross-linked hydrocolloid skin barrier that provides aggressive adherence and is designed for more than one day weartime....
Inquire...
Medicine Products: